Reaction
Non-Small Cell Lung Cancer Stage Iv reporting signals
As of the last recalculation, Non-Small Cell Lung Cancer Stage Iv appears in 356 FAERS reports alongside 8 co-occurring drug terms. The strongest observed disproportionality signal is CRIZOTINIB (PRR 118.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Crizotinib | 24 | 118.3 | 118.5 |
| Erlotinib Hydrochloride | 13 | 63.0 | 63.1 |
| Erlotinib | 10 | 62.1 | 62.1 |
| Pemetrexed | 19 | 54.7 | 54.7 |
| Pemetrexed Disodium | 23 | 37.7 | 37.7 |
| Dabrafenib | 11 | 31.5 | 31.5 |
| Osimertinib | 14 | 26.5 | 26.6 |
| Trametinib | 10 | 24.9 | 24.9 |